Decline in no-authorized generic deals, FTC reports

Fewer patent settlements involve agreements by branded drug companies to stay out of the generic marketplace, according to a Federal Trade Commission report. Only 21 agreements from Oct. 1, 2013, to Sept. 30, 2014 to settle patent disputes among pharmaceutical companies involved potential pay-for-delay settlements. That’s a decline from 29